Results of a phase III study comparing rituximab and lenalidomide with rituximab and standard chemotherapy for first line treatment of advanced follicular lymphoma.
Results of a phase III study comparing rituximab and lenalidomide with rituximab and standard chemotherapy for first line treatment of advanced follicular lymphoma.